Amgen Seeks Interchangeable Status for Its Amjevita (biosimilar, adalimumab)
Shots:
- Amgen plans to seek interchangeable status for its adalimumab biosimilar Amjevita. The company plans to launch Amjevita (biosimilar, adalimumab) in 2023 in the US
- Amgen reported that patients are currently being enrolled in P-III studies to support interchangeability designation in the US for biosimilars of Amjevita (adalimumab) and ABP 654 (ustekinumab)
- The company is expected the P-III results shortly for biosimilar Stelara (ustekinumab) to treat PsO and PsA while Eylea (aflibercept) for macular degeneration and Soliris (eculizumab) for PNH and aHUS
Ref: Fierce Pharma | Image: Amgen
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com